Carmustine Wafers and Chemotherapy for Glioblastoma
Author Information
Author(s): Masayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, Yukinori Akiyama, Takaaki Beppu, Shigeo Ohba, Toshiyuki Enomoto, Takahiro Ono, Yuta Mitobe, Mitsuto Hanihara, Yohei Mineharu, Joji Ishida, Kenichiro Asano, Yasuyuki Yoshida, Manabu Natsumeda, Sadahiro Nomura, Tatsuya Abe, Hajime Yonezawa, Ryuichi Katakura, Soichiro Shibui, Toshihiko Kuroiwa, Hiroyoshi Suzuki, Hidehiro Takei, Takuhiro Yamaguchi, Yoshiki Arakawa, Yukihiko Sonoda, Yuichi Hirose, Toshihiro Kumabe, Teiji Tominaga
Primary Institution: Tohoku University Graduate School of Medicine
Hypothesis
The study aimed to evaluate the efficacy and safety of carmustine wafers followed by radiation, temozolomide, and bevacizumab therapy in newly diagnosed glioblastoma patients with maximal resection.
Conclusion
The treatment may offer some benefit to survival in Japanese glioblastoma patients with maximal resection.
Supporting Evidence
- The estimated 2-year overall survival rate was 51.3%.
- Stroke occurred in 12% of cases.
- Patients were treated across 17 institutions in Japan.
Takeaway
Doctors tested a new treatment for brain cancer that includes special wafers and medicine, and it helped some patients live longer.
Methodology
This was a prospective phase II study involving glioblastoma patients who underwent maximal resection and received carmustine wafers, followed by radiation and chemotherapy.
Limitations
30% of initially enrolled patients did not proceed to the second registration, and information on salvage treatment was lacking.
Participant Demographics
{"age":{"median":64,"range":"33-75"},"sex":{"male":23,"female":22},"ethnicity":"Asian, Japanese"}
Statistical Information
Confidence Interval
{"overall_survival":"40.8-60.9%"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website